Ruijin Hospital

Running trials

• Not yet recruiting

  Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD

  NCT07698223· Phase 4· Chen Xiangmei· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions

  NCT07888335· Phase 4· Ruijin Hospital· Source

• Not yet recruiting

  A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

  NCT07720193· Phase 3· Nanjing Leads Biolabs Co.,Ltd· Source

• Recruiting

  Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

  NCT07885319· Phase 1/2· Ruijin Hospital· Source

• Not yet recruiting

  AI-Assisted Differentiation of Pancreatic Cystic Lesions Using EUS Images and Clinical Features

  NCT07919704· Ruijin Hospital· Source

• Not yet recruiting

  Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

  NCT07589400· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Not yet recruiting

  A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer

  NCT07928362· Ruijin Hospital· Source

• Not yet recruiting

  A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants

  NCT07884864· Phase 1· Ausper Biopharma Co., Ltd.· Source

• Not yet recruiting

  Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC

  NCT07890636· Phase 2· Ruijin Hospital· Source

• Recruiting

  Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  NCT07888140· Phase 3· Ruijin Hospital· Source

• Not yet recruiting

  Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT

  NCT07888348· Phase 1/2· Ruijin Hospital· Source

• Not yet recruiting

  HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer

  NCT07900789· Phase 3· Shanghai Hengrui Pharmaceutical Co., Ltd.· Source

• Recruiting

  Phase I/II Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

  NCT07733349· Phase 1/2· Shanghai UniXell Biotechnology Co., Ltd· Source

• Recruiting

  Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage

  NCT07876544· Phase 4· Shanghai Jiao Tong University School of Medicine· Source

• Recruiting

  Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers

  NCT07914556· Phase 1· Mabwell (Shanghai) Bioscience Co., Ltd.· Source

• Not yet recruiting

  A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy

  NCT07774585· Phase 1· Ruijin Hospital· Source

• Not yet recruiting

  Sphere-9 PAF China Study

  NCT07789925· Medtronic Cardiac Ablation Solutions· Source

• Not yet recruiting

  Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement

  NCT07812493· Phase 2· Pengpeng Xu· Source

• Not yet recruiting

  A Phase II Study of VB19055 in Uncontrolled or Resistant Hypertension

  NCT07833098· Phase 2· Zhejiang Yangli Pharmaceutical Technology Co., Ltd.· Source

• Not yet recruiting

  Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

  NCT07712588· Phase 2/3· Dizal Pharmaceuticals· Source

• Recruiting

  Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

  NCT07776522· Phase 2· West China Hospital· Source

• Recruiting

  A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

  NCT07784374· Phase 2· Genfleet Therapeutics (Shanghai) Inc.· Source

• Recruiting

  CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial

  NCT07769008· Ruijin Hospital· Source

• Not yet recruiting

  Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease

  NCT07741045· Phase 3· Hangzhou PhecdaMed Co., Ltd.· Source

• Recruiting

  STN-tTIS With Different Intervention Intervals Versus Standard Medical Treatment for Parkinson's Disease

  NCT07774312· Ruijin Hospital· Source

• Not yet recruiting

  Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer

  NCT07745790· Phase 2· Ruijin Hospital· Source

• Recruiting

  The Effect of Ablation Duration of Renal Denervation on Antihypertensive Efficacy

  NCT07876479· Ruijin Hospital· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Not yet recruiting

  Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

  NCT07664839· Phase 2· Shen yang· Source

• Not yet recruiting

  CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation

  NCT07672964· Phase 1· Ruijin Hospital· Source

• Not yet recruiting

  Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer

  NCT07683403· Phase 1/2· Fudan University· Source

• Recruiting

  An Extension Trial of GW 906 in Participants With Essential Hypertension

  NCT07879755· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Recruiting

  CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation

  NCT07662369· Phase 1/2· Ruijin Hospital· Source

• Not yet recruiting

  Local Field Potential Correlates of Neuropsychiatric Symptoms in Parkinson's Disease

  NCT07633379· King's College London· Source

• Recruiting

  Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

  NCT07607418· Phase 2· Ruijin Hospital· Source

• Recruiting

  Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia

  NCT07838714· Phase 1· Ruijin Hospital· Source

• Recruiting

  Study of SA+X in the Treatment of Newly Diagnosed AML

  NCT07548710· Phase 2· Ruijin Hospital· Source

• Recruiting

  Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

  NCT07310433· Phase 2· Yung NA· Source

• Recruiting

  Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

  NCT07569068· Phase 2· Ruijin Hospital· Source

• Not yet recruiting

  The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL

  NCT07548255· Phase 1· Ruijin Hospital· Source

• Recruiting

  LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

  NCT07556640· Phase 2· Ruijin Hospital· Source

• Recruiting

  Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification

  NCT07888374· Ruijin Hospital· Source

• Active, not recruiting

  Safety and Efficacy of Intrathecal NTF001 Injection in ALS

  NCT07618585· Phase 1· Ruijin Hospital· Source

• Recruiting

  Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases

  NCT07504471· Phase 2· Ruijin Hospital· Source

• Recruiting

  Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)

  NCT07352891· Beijing Anzhen Hospital· Source

• Recruiting

  Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer

  NCT07683845· Beijing Daxiang Biotech Co., Ltd· Source

• Recruiting

  A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

  NCT07372287· Phase 3· CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)

  NCT07310095· Phase 4· Xian-Janssen Pharmaceutical Ltd.· Source

Showing 50 of 194.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers16 recruiting
• Gastric and oesophageal cancer13 recruiting
• Pancreatic cancer13 recruiting
• Acute myeloid leukaemia12 recruiting
• High blood pressure12 recruiting
• Lung cancer11 recruiting
• Parkinson disease8 recruiting
• Coronary artery disease7 recruiting
• Hepatitis B6 recruiting
• Liver and biliary tract cancer6 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Mantle cell lymphoma5 recruiting
• Myelodysplastic syndromes5 recruiting
• Acute lymphoblastic leukaemia4 recruiting
• Alzheimer disease4 recruiting
• Bronchiectasis4 recruiting
• Colorectal cancer4 recruiting
• Fatty liver disease (MASLD/MASH)4 recruiting
• Sarcoma4 recruiting
• Asthma3 recruiting
• Crohn's disease3 recruiting
• Heart failure3 recruiting
• Liver cirrhosis3 recruiting
• Multiple system atrophy3 recruiting
• Prostate cancer3 recruiting
• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• Cervical cancer2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Follicular lymphoma2 recruiting
• IgA nephropathy2 recruiting
• Neuroendocrine tumours2 recruiting
• Ulcerative colitis2 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diabetic eye disease1 recruiting
• Essential tremor1 recruiting
• Hepatitis C1 recruiting
• Hodgkin lymphoma1 recruiting
• Macular degeneration1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Primary biliary cholangitis1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting
• Turner syndrome1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Da-Cheng-Qi Decoction in Severe Acute Pancreatitis

  NCT07816900· Shanghai Jiao Tong University School of Medicine· Source

• Completed

  The 10-Year Extended Follow-up of the DACAB Trial

  NCT07480629· Ruijin Hospital· Source

• Completed

  6 Weeks Right-Amygdala TIS for Depression

  NCT07059143· Ruijin Hospital· Source

• Completed

  STN-tTIS Modulates Parkinson Motor Symptoms With and Without Medications

  NCT06980935· Ruijin Hospital· Source

• Completed

  A Prospective, Multicenter, Portable Pulmonary Function Comparison Study Aimed at Evaluating the External Clinical Validation of the Chronic Obstructive Pulmonary Disease Auxiliary Diagnostic Software LH-002 (Version: 2.0.0) in Clinical Diagnosis Accuracy

  NCT07888712· Ruijin Hospital· Source

• Completed

  [18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients

  NCT06738862· Ruijin Hospital· Source

• Completed

  A Study to Evaluate the Efficacy and Safety in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT07790120· Phase 3· Shenzhen Salubris Pharmaceuticals Co., Ltd.· Source

• Completed

  First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure

  NCT06621576· Early phase 1· Ruijin Hospital· Source

• Recruiting

  FeNO Detection in Asthma Diagnosis: A New Technology Approach

  NCT06852911· Novlead Inc.· Source

• Completed

  Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

  NCT06538623· Phase 2· Ruijin Hospital· Source

• Completed

  Amygdala TIS for Depression

  NCT06477276· Ruijin Hospital· Source

• Completed

  An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

  NCT06421740· AbbVie· Source

• Completed

  Validation of the Reliability and Validity of the New Endoscopic Scoring System for Ulcerative Colitis (CAT-DESIRE Score) and Verification of Its Clinical Practicability

  NCT07608198· Xijing Hospital of Digestive Diseases· Source

• Completed

  Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis

  NCT06164093· Ruijin Hospital· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source

• Completed

  Temporal Interference Stimulation in Major Depressive Disorder: A Pilot Feasibility Study

  NCT07888387· Ruijin Hospital· Source

• Completed

  Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

  NCT05959083· AbbVie· Source

• Completed

  Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

  NCT06589752· Ruijin Hospital· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Completed

  Safety and Efficacy Study of Parkinson's Disease Gene Therapy Drug (BBM-P002)

  NCT05822739· Early phase 1· Xiangya Hospital of Central South University· Source

• Terminated

  Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

  NCT05721222· Phase 1/2· Genmab· Source

• Completed

  Chinese Endocrinologists Health Education Study

  NCT05715307· Shanghai Jiao Tong University School of Medicine· Source

• Completed

  Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

  NCT05528419· Phase 4· Shanghai Jiao Tong University School of Medicine· Source

• Terminated

  Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

  NCT05611853· Phase 1/2· BioNova Pharmaceuticals (Shanghai) LTD.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Asymmetric Targeted DBS for PD With PIGD

  NCT05397340· Ruijin Hospital· Source

• Withdrawn

  A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

  NCT05365100· Phase 1/2· BioNova Pharmaceuticals (Shanghai) LTD.· Source

• Completed

  A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

  NCT05394805· AbbVie· Source

• Completed

  A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

  NCT04974749· Phase 3· Takeda· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

  NCT04942834· Ruijin Hospital· Source

• Completed

  DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR)

  NCT04635098· Ruijin Hospital· Source

• Terminated

  Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

  NCT05263271· Phase 1· Changchun GeneScience Pharmaceutical Co., Ltd.· Source

• Completed

  Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

  NCT04435197· Phase 2· Ruijin Hospital· Source

• Completed

  IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

  NCT04298879· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  Mid-Q Response Study

  NCT04180696· Medtronic Cardiac Rhythm and Heart Failure· Source

• Completed

  Gastrodia and Uncaria Recipe in Treating Stage-one Hypertension: an Evidence-based Optimization Study

  NCT04035824· Phase 4· Shanghai Institute of Hypertension· Source

• Completed

  TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03952091· Phase 3· TJ Biopharma Co., Ltd.· Source

• Completed

  Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients

  NCT03946514· Phase 4· Shanghai Jiao Tong University School of Medicine· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· AbbVie· Source

• Completed

  A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  NCT03069352· Phase 3· AbbVie· Source

• Completed

  Cryo Global Registry

  NCT02752737· Medtronic Cardiac Ablation Solutions· Source

• Completed

  Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer

  NCT02966483· Sun Yat-sen University· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Colorectal cancer68 works · 5 trials
• Type 2 diabetes66 works · 1 trial
• Gastric and oesophageal cancer63 works · 18 trials
• Parkinson disease59 works · 15 trials
• Pancreatic cancer45 works · 14 trials
• Acute myeloid leukaemia37 works · 15 trials
• Crohn's disease36 works · 8 trials
• Osteoarthritis34 works · 0 trials
• Diffuse large B-cell lymphoma32 works · 7 trials
• Rheumatoid arthritis25 works · 0 trials
• Ulcerative colitis23 works · 5 trials
• Psoriasis22 works · 0 trials
• Triple-negative breast cancer21 works · 0 trials
• Kidney cancer21 works · 1 trial
• Thyroid cancer17 works · 1 trial
• Obstructive sleep apnoea15 works · 1 trial
• Neuroendocrine tumours14 works · 2 trials
• Hodgkin lymphoma13 works · 1 trial
• IgA nephropathy11 works · 3 trials
• Haemophilia11 works · 0 trials
• Myelodysplastic syndromes11 works · 6 trials
• Hepatitis B11 works · 8 trials
• Dermatomyositis and polymyositis (myositis)10 works · 1 trial
• High blood pressure10 works · 20 trials
• Hypertrophic cardiomyopathy9 works · 0 trials
• Polycystic ovary syndrome8 works · 0 trials
• Multiple system atrophy8 works · 4 trials
• Fabry disease7 works · 1 trial
• Follicular lymphoma6 works · 4 trials